Investigational New Drug Application : comparemela.com

Investigational New Drug Application


Shares of Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) hit a new 52-week low of $4.72 on Monday and was trading lower by more than 4 percent.
Ariad Pharmaceuticals announced earlier in the day that the U.S. Food and Drug Administration has completed its review of the company's Investigational New... Read More...
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:

Related Keywords

, Scopus Biopharma Inc , Ariad Pharmaceuticals , Drug Administration , Ariad Pharmaceuticals Inc , Diamedica Therapeutics Inc , Nasdaq , Investigational New Drug Application , Did Scopus Biopharma , Stock More Than Double , Ischemic Strokemonday , Investigational New Drug , Acute Ischemic Stroke , Typec Meeting Responses , Generalized Anxiety Disorder , Project Lucy , Investigational New , நாஸ்டாக் , ப்ராஜெக்ட் லூசி ,

© 2025 Vimarsana